Showing results (2331-2340 of 2,352) with videos related to

Sort By:
Pageof 236
Lung|April 27, 2026
High Serum IgE is Associated with Risk of Severe Exacerbations Among Non-Eosinophilic BronchiectasisTing-Wei Kao, Ya-Hui Wang, Chia-Ling Chang, et al.
Nature Biotechnology|October 18, 2011
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaquesGuangmei Yan, Guojie Zhang, Xiaodong Fang, et al.
Open Forum Infectious Diseases|August 15, 2024
Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis BronchiectasisPing-Huai Wang, Chin-Chung Shu, Chau-Chyun Sheu, et al.
Genome Biology|January 23, 2015
Genomes of the rice pest brown planthopper and its endosymbionts reveal complex complementary contributions for host adaptationJian Xue, Xin Zhou, Chuan-Xi Zhang, et al.
Science (New York, N.Y.)|August 29, 2009
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx)Qingyou Xia, Yiran Guo, Ze Zhang, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
ERJ Open Research|March 12, 2025
The impact of COPD-bronchiectasis association on clinical outcomes: insights from East Asian cohorts validating the ROSE criteriaYen-Fu Chen, Chia-Ling Chang, Hsin-Han Hou, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Pageof 236